High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei

British Journal of Haematology

Volumn 155, Issue 1, 2011, Pages 125-128

  Rakheja, Dinesh ^a,b   Konoplev, Sergej ^c   Su, Mu ^a   Wheeler, David ^d   Muzny, Donna M ^d   Ruvolo, Vivian R ^c   Collins, Robert ^a   Karandikar, Nitin J ^a   Andreeff, Michael ^c   Medeiros, Leonard Jeffrey ^c   Chen, Weina ^a,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Children's Medical Center   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Acute leukaemia; Acute myeloid leukaemia; Cuplike; FLT3; IDH; NPM1

Indexed keywords

2 HYDROXYGLUTARIC ACID; CD135 ANTIGEN; CD34 ANTIGEN; HLA DR ANTIGEN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; NUCLEOPHOSMIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; FLT3 GENE; GENE; GENE MUTATION; GIEMSA STAIN; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; IMMUNOPHENOTYPING; INCIDENCE; LETTER; LIQUID CHROMATOGRAPHY; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; NPM1 GENE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL NUCLEUS; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; YOUNG ADULT;

EID: 80052586077     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08646.x     Document Type: Letter

References (10)

1. van den Bent, M.J., Dubbink, H.J., Marie, Y., Brandes, A.A., Taphoorn, M.J., Wesseling, P., Frenay, M., Tijssen, C.C., Lacombe, D., Idbaih, A., van Marion, R., Kros, J.M., Dinjens, W.N., Gorlia, T. & Sanson, M. (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 16, 1597-1604.
2. Chen, W., Konoplev, S., Medeiros, L.J., Koeppen, H., Leventaki, V., Vadhan-Raj, S., Jones, D., Kantarjian, H.M., Falini, B. & Bueso-Ramos, C.E. (2009) Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer, 115, 5481-5489.
3. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J., Thompson, C.B., Levine, R.L. & Melnick, A. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553-567.
4. Kroschinsky, F.P., Schakel, U., Fischer, R., Mohr, B., Oelschlaegel, U., Repp, R., Schaich, M., Soucek, S., Baretton, G., Ehninger, G. & Thiede, C. (2008) Cup-like acute myeloid leukemia: new disease or artificial phenomenon? Haematologica, 93, 283-286.
5. Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrozek, K., Margeson, D., Holland, K.B., Whitman, S.P., Becker, H., Schwind, S., Metzeler, K.H., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28, 2348-2355.
6. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636-3643.
7. Rakheja, D., Mitui, M., Boriack, R.L. & DeBerardinis, R.J. (2011) Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatric Blood and Cancer, 56, 379-383.
8. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., Rabinowitz, J.D., Carroll, M., Su, S.M., Sharp, K.A., Levine, R.L. & Thompson, C.B. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225-234.
9. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Xiao, M.T., Liu, L.X., Jiang, W.Q., Liu, J., Zhang, J.Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.H., Lei, Q.Y., Guan, K.L., Zhao, S.M. & Xiong, Y. (2011) Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of alpha-Ketoglutarate-Dependent Dioxygenases. Cancer Cell, 19, 17-30.
10. Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K.W., Velculescu, V.E., Vogelstein, B. & Bigner, D.D. (2009) IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine, 360, 765-773.